This directory of institutions that collaborate and conduct investigations as pediatric cancer research consortia was compiled by Elena Gerasimov of Kids v Cancer. It includes consortia that identify themselves as such, are built via collaboration of multiple sites/institutions, and are either focused on pediatric cancer exclusively or include pediatric cancer patients in their studies. The scope of work of the consortia ranges from basic research, repositories and registries to genomic analyses and clinical trials.

Contact information is included in this document to help academic researchers, investigators and industry to connect in their search for the cures.

An electronic version of this directory is available on Kids v Cancer’s website homepage, www.kidsvcancer.org. Please check our website for the most updated version.

This directory is focused on consortia operating primarily in the United States and does not include single institutions. Future versions of this document will include additional non-U.S. consortia, as well as a list of hospitals/universities conducting single institution trials.

To suggest a consortium for addition to the directory, either U.S. or non-U.S.-based, please contact Elena Gerasimov, Director of Programs, Kids v Cancer, at Elena@kidsvcancer.org.
Contents:

Beat Childhood Cancer (BCC, formerly NMTRC) .............................................................. 5
Children's Oncology Group (COG) .................................................................................. 6
Children's Oncology Group Phase 1 & Pilot Consortium ............................................... 7
Children's Brain Tumor Tissue Consortium (CBTTC) ..................................................... 8
Collaborative Ependymoma Research Network (CERN) ............................................... 9
Collaborative Network for Neuro-oncology Clinical Trials (CONNECT) .................... 10
Dana Farber Cancer Institute Acute Lymphoblastic Leukemia (DFCI-ALL) Consortium ... 11
DIPG Preclinical Consortium ......................................................................................... 12
Fred Hutchinson/University of Washington Cancer Consortium ................................. 13
Genomic Assessment Improves Novel Therapy Consortium (GAIN) ......................... 14
Innovative Therapies for Children with Cancer (ITCC) Consortium .......................... 15
Institute for Pediatric Innovation's Pediatric Hospital Consortium .............................. 17
International Childhood Cancer Cohort Consortium at National Cancer Institute, Division of Cancer Epidemiology and Genetics (I4C) .................................................. 18
Malignant Germ Cell International Consortium (MaGiC) ............................................ 19
Medulloblastoma Advanced Genomics International Consortium (MAGIC) ............... 20
Mount Sinai Acute GVHD International Consortium (MAGIC) .................................. 21
National Experimental Therapeutics Consortium (NEXT) ........................................... 23
NCI National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP) ................................................................. 24
New Approaches to Neuroblastoma Therapy (NANT) ............................................... 26
North American Consortium for Histiocytosis (NACHO) ........................................ 27
North American Pediatric Aplastic Anemia Consortium (NAPAAC) ............................ 28
Oncofertility Consortium .......................................................................................... 29
Pacific Pediatric Neuro-Oncology Consortium (Pnoc) ............................................... 30
Pediatric Blood and Marrow Transplant Consortium (PBMTC) ............................... 31
Pediatric Brain Tumor Consortium (PBTC) .................................................................. 33
Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC) .... 34
Pediatric Patient Reported Outcomes in Chronic Diseases Consortium (PEPR) .................. 35
Pediatric Preclinical Testing Consortium (PPTC) .................................................................. 36
Pediatric Proton Consortium Registry (PPCR) ...................................................................... 37
Sanford Children’s Genomic Medicine Consortium .................................................................. 38
Sarcoma Alliance for Research through Collaboration (SARC) .............................................. 39
South Plains Oncology Consortium (SPOC) ........................................................................... 41
Southwest Oncology Group Cancer Research Network (SWOG) ............................................ 42
St. Jude Children’s Research Hospital .................................................................................. 43
Sunshine Project Consortium ............................................................................................... 44
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) ................................. 45
Treehouse Childhood Cancer Initiative .................................................................................. 46
University of California Cancer Consortium ......................................................................... 47
Beat Childhood Cancer (BCC, formerly NMTRC)

An international group of researchers and hospitals that collaborate to conduct childhood cancer clinical trials. These trials are based on the research from a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies and technologies. Neuroblastoma, medulloblastoma and solid mass childhood cancers are the primary research focus for BCC, which is currently conducting 8 clinical trials and has closed 10 trials.

MEMBERS:
Cardinal Glennon Children’s Medical Center
Levine Children’s Hospital
Medical University of South Carolina
Children’s Hospital at Vanderbilt
Connecticut Children’s Medical Center
Penn State Milton S. Hershey Medical Center and Children’s Hospital
Baylor College of Medicine
Floating Hospital for Children at Tufts Medical Center
Helen DeVos Children’s Hospital
Arnold Palmer Hospital for Children
Children’s Mercy Hospitals and Clinics
Mass General Hospital
University of Hawaii Kapiolani Medical Center for Women and Children
Phoenix Children’s Hospital
Intermountain Primary Children’s Hospital
Dell Children’s Blood and Cancer Center
Rady Children’s Hospital
Children’s Health
Children’s Hospitals and Clinics of Minnesota
UCSF Benioff Children’s Hospital
Kentucky Children’s Hospital
Children’s Cancer Institute, American University of Beirut – Lebanon
Nationwide Children’s Hospital
Johns Hopkins All Children’s Hospital
Arkansas Children’s Hospital
Randall Children’s Hospital at Legacy Emanuel
Children’s Hospital of Georgia
Hackensack University Medical Center

CHAIR:
Giselle Sholler, MD
Helen DeVos Children’s Hospital
100 Michigan St. NE MC272
Grand Rapids, MI 49503
Phone: (616) 267-0335
E-mail:
giselle.sholler@helendevoschildrens.org

CONTACT:
Genevieve Bergendahl, MSN, PNP, CCRC
Clinical Program Director, Beat Childhood Cancer
100 Michigan Avenue NE MC 272
Grand Rapids, MI 49503
Genevieve.bergendahl@helendevoschildrens.org

WEBSITE:
https://beatcc.org/
Children’s Oncology Group (COG)

COG is a National Cancer Institute supported clinical trials group. With more than 9,000 experts in childhood cancer at more than 200 leading children’s hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe, COG is the world’s largest organization devoted exclusively to childhood and adolescent cancer research. More than 90% of children and adolescents diagnosed with cancer each year in the U.S. are cared for at COG’s member institutions.

The Children’s Oncology Group has nearly 100 active clinical trials open at any given time. COG partners with industry from laboratory discovery to all phases of clinic trials.

COG’s Hyundai Hope On Wheels biorepository, located at the Research Institute of Nationwide Children's Hospital, contains tissue from more than 32,000 children with childhood cancer and related diseases. It is the largest pediatric cancer biospecimen bank in the U.S.

MEMBERS:

Over 200 member institutions.
The full list:
https://www.childrensoncologygroup.org/index.php/locations/

LEADERSHIP:

Group Chair
Peter C. Adamson, MD
The Children's Hospital of Philadelphia
3501 Civic Center Blvd, CTRB 10060
Philadelphia, PA 19104
Tel: (215) 590-6359
Fax: (215) 590-7544
Email: adamson@email.chop.edu

Group Vice-Chair
Susan M. Blaney, MD
Texas Children’s Cancer Center / Baylor College of Medicine
6621 Fannin Street, CC 1410.00
Houston, TX 77030-2399
Tel: (832) 822-1482
Email: smblaney@txch.org

CONTACT:

COG Operations Center
222 E. Huntington Drive, Suite 100
Monrovia, CA 91016
Tel: (626) 241-1500
Fax: (626) 445-4334

General questions:
HelpDesk@childrensoncologygroup.org

Membership questions: MembershipInfo@childrensoncologygroup.org

WEBSITE:

https://childrensoncologygroup.org/
Children’s Oncology Group Phase 1 & Pilot Consortium

Founded in 2002, the consortium’s primary objective is to expeditiously develop and implement pediatric phase I and pilot studies, integrating advances in cancer biology and therapy into the treatment of childhood cancer. The consortium conducts pilot studies of promising multi-agent regimens. During the past 5 years over 20 different new agents/combinations were studied. Building upon the success of COG Phase 1 & Pilot Consortium, Pediatric Early Phase-Clinical Trial Network (PEP-CTN) is comprised of 21 pediatric oncology programs. The PEP-CTN designs and conducts pediatric early phase trials including phase 1 trials that often include phase 2 expansion cohorts, and pilot studies of novel agents/regimens.

MEMBERS:
Ann and Robert H Lurie Children's Hospital of Chicago
Baylor College of Medicine
C S Mott Children's Hospital
Children's Healthcare of Atlanta - Egleston
Children's Hospital Colorado
Children's Hospital of Alabama
Children's Hospital of Los Angeles
Children's Hospital of Philadelphia
Children's Hospital of Pittsburgh of UPMC
Children's National Medical Center
Children's Hospital of Orange County
Cincinnati Children's Hospital Medical Center
Columbia University/Herbert Irving Cancer Center
Dana-Farber/Harvard Cancer Center
National Institutes of Health Clinical Center
Riley Hospital for Children
Saint Jude Children's Research Hospital
Seattle Children's Hospital
UCSF Medical Center-Mission Bay
University of Minnesota/Masonic Cancer Center
Washington University School of Medicine

PEP-CTN CHAIR AND DVL VICE-CHAIR
Dr. Brenda J. Weigel, MD
University of Minnesota Medical Center-Fairview
Department of Pediatrics, Hem/Onc/BMT
Tel: 612 626-5501
Fax: 612 624-3913
Email: weige007@umn.edu

PEP-CTN VICE-CHAIR
Dr. Elizabeth Fox, MD
Children’s Hospital of Philadelphia
Division of Oncology
Tel: 267 425-3010
Fax: 267 425-0113
Email: foxe@email.chop.edu

WEBSITE:
https://ctep.cancer.gov/MajorInitiatives/Childrens_Oncology_Group.htm
https://ctep.cancer.gov/initiativesPrograms/pep-ctn.htm

Houston, TX 77030-2399
Tel: (832) 822-1482
Email: smblaney@txch.org

DVL CHAIR:
Susan M. Blaney, MD
Texas Children’s Cancer Center / Baylor College of Medicine
6621 Fannin Street, CC 1410.00
Children's Brain Tumor Tissue Consortium (CBTTC)

The CBTTC is a multi-institutional research program consisting of 16 institutions dedicated to the study and treatment of childhood brain tumors. The CBTTC has developed a network of informatics, data applications, a biorepository, the largest clinically annotated pediatric brain tumor database in the world with over 2,600 patients enrolled. CBTTC collects high-quality brain tumor biospecimens and associated clinical data to facilitate the genomic analysis of biospecimens. Full members are traditionally larger academic institutions willing to commit to submitting 75% of all pediatric brain tumor specimens to the CBTTC. CBTTC data are integrated with PNOC clinical trial data in near-real time. It released the first dataset of the Pediatric Brain Tumor Atlas in 2018.

MEMBERS:

Children's Hospital of Philadelphia
Seattle Children's
UPMC Children's Hospital of Pittsburgh
Ann & Robert H. Lurie Children's Hospital of Chicago
Benioff Children’s Hospital (UCSF)
Stanford University/Lucile Packard Children's Hospital
Meyer Children's Hospital (Florence, Italy)
Weill Cornell Medicine Pediatric Brain and Spine Center
Children’s National Health System
Joseph M. Sanzari Children’s Hospital at Hackensack University Medical Center
Children’s Hospital of Orange County
University of California Santa Cruz – Treehouse Childhood Cancer Initiative
The Beijing Tiantan Hospital Neurosurgery Center (Beijing, China)
Genebank (Beijing Genomics Institute – Shenzhen, China)
Dayton Children's Hospital
The Hudson Institute of Medical Research (Melbourne, Australia)

EXECUTIVE CHAIR:

Angela Waanders, MD
Principal Investigator from core institution
Children’s Hospital of Philadelphia

CONTACT:

CBTTC Operations Center
The Children’s Hospital of Philadelphia
2716 South Street, #12412
Philadelphia PA 19146

Email: operations@cbttc.org

WEBSITE:

https://cbttc.org/
Collaborative Ependymoma Research Network (CERN)

Founded in 2006, CERN is a network of adult and pediatric neuro-oncologists who specialize in treating ependymoma. The CERN Foundation has supported four separate ependymoma clinical trials – two for adult patients and two for pediatric patients. One CERN trial is currently open.

MEMBERS:

Children’s Hospital of Chicago
Children’s Hospital of Colorado
Children’s Hospital of Los Angeles
Children’s National Medical Center
Cincinnati Children’s Hospital Medical Center
Dana-Farber and Harvard Cancer Center
Henry Ford Hospital
Huntsman Cancer Institute, University of Utah
Mayo Clinic
Memorial Sloan-Kettering Cancer Center
National Institutes of Health
Ohio State University Wexner Medical Center
St. Jude Children’s Research Hospital
Stanford Children’s Health
The Hospital for Sick Children (Sick Kids)
The University of Texas MD Anderson Cancer Center
University of Miami
University of Pittsburgh Medical Center
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
Cambridge University Hospital – United Kingdom
Hopp Children’s Cancer Center at the NCT Heidelberg
University of Torino – Italy

LEADERSHIP:

Kimberly Wallgren
President

Chas Haynes
Executive Director

CONTACT:

E-mail: Administrator@cern-foundation.org
Tel. (844) 237-6674.
Mailing address:
PO Box 217, Zionsville, IN 46077

WEBSITE:

http://www.cern-foundation.org
Collaborative Network for Neuro-oncology Clinical Trials (CONNECT)

The Collaborative Network for Neuro-oncology Clinical Trials (CONNECT) is an international network of pediatric cancer centers with the objective to improve outcomes for children with newly-diagnosed, high-risk brain tumors. It conducts small, pilot studies of high-risk pediatric brain tumors (such as DIPG) to assess feasibility and early efficacy of incorporating promising new therapies into established frontline therapeutic regimens. Once combinations are shown to be safe and effective, CONNECT works collaboratively with larger consortia to help move these discoveries into larger trials.

MEMBERS:
Anne & Robert H. Lurie Children's Hospital of Chicago
Baylor College of Medicine
Children's Hospital of Colorado
Children's National Medical Center
Cincinnati Children's Hospital Medical Center
Dana-Farber Cancer Center
Hospital for Sick Children (Canada)
McMaster Children's (Canada)
Montreal Children's Hospital (Canada)
Seattle Children's Hospital
Lady Cilento Children's Hospital (Australia)
Princess Margaret Hospital for Children (Australia)
Sydney Children's Hospital (Australia)
Deutsches Krebsforschungszentrum (German Cancer Research Center)
Great Ormond Street Hospital, United Kingdom
VU University Medical Center, Netherlands

PRINCIPAL INVESTIGATORS:
Maryam Fouladi, MD, MSc, Chair
Darren Hargrave, MB, ChB (Hons), MD Co-Chair

CONTACT:
Via webpage:
https://connectconsortium.org/contact

WEBSITE:
https://connectconsortium.org/
Dana Farber Cancer Institute Acute Lymphoblastic Leukemia (DFCI-ALL) Consortium

Founded in 1981 to help advance research into effective treatments for acute lymphoblastic leukemia, the consortium has been conducting clinical trials in childhood ALL for over 30 years. DFCI-ALL pioneered the use of a minimal residual disease test that predicts subsequent risk of relapse. The consortium is a leader in the study of asparaginase, an important chemotherapeutic agent in the treatment of childhood ALL.

MEMBERS:

Columbia Presbyterian Medical Center
Hospital Sainte Justine
Centre Hospitalier Universitaire de Quebec
Fairfax/Inova
LDS Hospital
Maine Children's Cancer Program
McMaster University MC
Montefiore/Albert Einstein
Ohio State University Med Center
Rhode Island Hospital (Hasbro)
San Jorge Children's Hospital
Tulane University Hospital and Clinic
University of Rochester Medical Center
Queens University/Kingston Hospital
Cancer Care Manitoba
Cross Cancer Institute
Saskatchewan Cancer Agency
Hospital Maisonneuve-Rosemont
London Health Science Center
Tom Baker Cancer Center
Queen Elizabeth II
Vancouver General Hospital

Centers in Follow-Up Only:

Eastern Maine Medical Center
Mt. Sinai Medical Center
Ochsner Clinic
University of Mass Medical Center

PRINCIPAL INVESTIGATORS:

Stephen Sallan, MD
Tel: 617.632.3316, 617.632.3318
Email: Stephen_Sallan@dfci.harvard.edu

or Admin. Secretary: Sharon Thornhill
Sharon_Thornhill@dfci.harvard.edu

Lewis Silverman, MD
Director of Clinical Research and Clinical Care, Department of Pediatric Oncology
Professor of Pediatrics, Harvard Medical School
Tel: 617-632-6191
E-mail: lewis_silverman@dfci.harvard.edu

Dana-Farber Cancer Institute
Pediatric
450 Brookline Ave
Boston, MA 02115
Tel: 617.632.3000
www.dana-farber.org

CONTACT:

DFCI/ALL Consortium
Dana-Farber Cancer Institute (Coordinating Center)
450 Brookline Ave
Boston, MA 02215
Phone: 617.632.3754
Fax: 617.582.8135

WEBSITE:

http://allconsortium.dfcf.harvard.edu/
DIPG Preclinical Consortium

Formed in 2011 and funded by patient groups and parent organizations, this consortium brings together international basic and translational scientists and physicians who focus on DIPGs and on a bench-to-bedside approach to rationally target therapy for children with DIPGs. Working to identify pathways in DIPGs to test and prioritize current molecularly targeted agents, the consortium has discovered a target and started a clinical trial. It accepts and disseminates DIPG research autopsy tissue.

MEMBERS:

Children's Cancer Therapy Development Institute (Charles Keller)  
Oregon Health and Science University (Kellie Nazemi, Nate Selden, Dan Guillaume Catie Grasso and Paul Spellman)  
Duke University Medical Center (Oren Becher)  
Stanford University (Michelle Monje)  
Cincinnati Children's Hospital Medical Center (Maryam Fouladi)  
Baylor College of Medicine (Xiao Nan Li)  
University of Toronto (Cynthia Hawkins)  
VU Cancer Center of Amsterdam (Dannis G. van Vuurden, and Ester Hulleman)  
Institut Gustave-Roussy, Villejuif France (Jacques Grill)  
Johns Hopkins University (Eric H. Raabe)  
NIH (Katherine Warren, Paul Meltzer, Martha Quezado)  
Nationwide Children's Hospital (Mariko DeWire)  
University of Florida - Gainesville (Dennis Steindler)  
University of Navarra, Madrid, Spain (Marta Alonso)

CONTACT:

Charles Keller MD,  
Scientific Director  
Children's Cancer Therapy Development Institute  
Tel. (801) 232-8038  
E-mail: charles@cc-TDI.org

WEBSITE:

http://cc-TDI.org
Fred Hutchinson/University of Washington Cancer Consortium

The Fred Hutchinson/University of Washington Cancer Consortium, an NCI-designated Comprehensive Cancer Center, brings together over 620 faculty members. The Consortium conducts both adult and pediatric clinical trials. The Consortium is the home of 11 Clinical Coordinating Centers worldwide and NIH-supported Specialized Programs of Research Excellence (SPOREs) in cancer. It currently has 370 open trials, including 114 trials for pediatric patients.

MEMBERS:
Fred Hutchinson Cancer Research Center
The University of Washington
Seattle Children's Hospital
Seattle Cancer Care Alliance

DIRECTOR:
Gary Gilliland, MD, PhD
President and Director,
Fred Hutchinson Cancer Research Center
Tel. (206) 667-6767
E-mail: gary@fredhutch.org

CONTACT:
1100 Fairview Ave N,
Seattle, WA 98109
Email: cancerconsortium@fredhutch.org

WEBSITE:
http://www.cancerconsortium.org/en/about.html
Genomic Assessment Improves Novel Therapy Consortium (GAIN)

The GAIN Consortium includes more than 20 pediatric oncology academic medical centers, led by Dana Farber Cancer Institute. The primary goal of GAIN is to offer molecular diagnostics to children with solid tumors and leukemia. The GAIN consortium study is a follow up to the first study, Individualized Cancer Therapy (iCat), that demonstrated the feasibility of bringing clinical genomic sequencing to pediatric oncology practice.

MEMBERS:
University of California San Francisco
Children's Hospital Colorado
Children's National Medical Center
University of Chicago Comer Children's Hospital
Boston Children's Hospital
Dana-Farber Cancer Institute
Columbia University Medical Center
Nationwide Children's Hospital
University of Texas Southwestern Medical Center at Dallas
University of Utah Children's Medical Center
Seattle Children's Hospital

PRINCIPAL INVESTIGATOR:
Katherine Janeway, MD
Tel. 617-632-4994
E-mail: KJaneway@Partners.org

WEBSITE:
https://cri.uchicago.edu/portfolio/gain-consortium/
https://clinicaltrials.gov/ct2/show/NCT02520713
Innovative Therapies for Children with Cancer (ITCC) Consortium

ITCC includes 56 European Pediatric Oncology Departments in 14 countries with expertise in conducting early phase trials in children and adolescents, and 25 European research laboratories. The aim ITCC is to develop novel therapies for the treatment of pediatric and adolescent cancers in cooperation with regulatory bodies, pharmaceutical enterprises, parents and patients. ITCC was established as a European Category 1 Network for Pediatric Research at the European Medicines Agency (EnprEMA). ITCC National Coordinating Centers Consortium includes ITCC institutions coordinate the delivery of the trials in their countries. The Consortium also includes institutions that act as the sole, centralized ITCC recruiting site for their country. ITCC is currently conducting 6 trials for leukemia and 15 trials for solid tumors.

MEMBERS:

AUSTRIA
CCRI, Vienna

BELGIUM
Ghent University, Ghent

DENMARK
Rigshospitalet, Copenhagen

FINLAND
Tampere University Hospital, Tampere

FRANCE
CHU Bordeaux, Bordeaux
Centre Oscar Lambret, Lille
Centre Léon Bérard, Lyon
La Timone, Marseille
CHU Nantes, Nantes
Trousseau, Paris
Hopital Robert Debré, Paris
Institut Curie, Paris
CHU Toulouse, Toulouse
CHU Nancy, Vandoeuvre
Institut Gustave Roussy, Villejuif

GERMANY
Charité, OHC, Berlin
Universitätsklinikum, Frankfurt
Pädiatrische Hämatologie und Onkologie Zentrum, Freiburg
Hannover Medical School, Hannover

University Medical Center Schleswig-Holstein, Kiel
UniversitätsKlinikum, Münster
Olghospital Padiatiches, Stuttgart
Hopp Children’s Cancer Center at the NCT Heidelberg, Heidelberg
University Children's Hospital, Essen

IRELAND
Our Lady's Hospital for Sick Children, Dublin

ISRAEL
Schneider Children's Medical Center of Israel, Petah-Tikva
Rambam Medical Center, Haifa

ITALY
Gaslini Institute, Genova
Istituto Nazionale Tumori, Milano
Ospedale San Gerardo, Monza
Azienda Ospedaliera, Padova
Università Cattolica del Sacro Cuore, Roma
Ospedale Bambin Gesù, Roma
Università di Torino, Torino

SPAIN
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Universitario La FE, Valencia
Hospital Nino Jesus, Madrid
Hospital Sant Joan de Deu, Barcelona
La Paz University Hospital, Madrid
SWEDEN
Astrid Lindgren Children's Hosp, Karolinska, Stockholm
Queen Silvia Children's and Adolescents' Hospital, Gothenburg

SWITZERLAND
University Children's Hospital, Zurich
CHUV University Hospital Vaudois, Lausanne

THE NETHERLANDS
AMC, Amsterdam
Erasmus, Rotterdam
Princess Maxima Center, Utrecht

THE UK
Birmingham Children's Hospital, Birmingham
Royal Hospital, Bristol
Addenbrookes Hospital, Cambridge
Yorkhill Hospital, Glasgow
St James University Hospital, Leeds
Great Ormond Hospital, London
Children's Hospital, Manchester
Newcastle University, Newcastle
Royal Marsden, Sutton
Alder Hey Children's NHS Foundation Trust, Liverpool
University College London Hospital, London

RESEARCH LABORATORIES
Charité University, Berlin, Germany
Hopp Children's Cancer Center at the NCT Heidelberg, Heidelberg, Germany
Essen University Children's Hospital, Essen, Germany
Ghent University Hospital, Ghent, Belgium
Goethe University Frankfurt, Frankfurt, Germany
GOSH, London, The UK
Gustave Roussy, Villejuif, France
Hamburg University Medical Center, Hamburg, Germany
Hannover Medical School, Hannover, Germany
Institut Curie, Paris, France
Institute of Cancer Research, London, The UK
Istituto Rizzoli Bologna, Bologna, Italy
Ludwig Maximilian University Munich, Munich, Germany
Newcastle University, Newcastle, The UK
Prinses Maxima Centrum, Utrecht, Netherlands
Rigshospitalet Copenhagen, Copenhagen, Denmark
Robert Debré, Paris, France
St Anna Kinderkrebsforschung, Vienna, Austria
UCL, London, The UK
Universitaetsklinikum Muenster, Muenster, Germany
Wellcome Trust, London, The UK
Wuerzburg University, Wuerzburg, Germany
Zuerich University Children's Hospital, Zuerich, Switzerland
Tampere University, Tampere, Finland
Universitaetsklinikum Halle, Halle, Germany

CONTACT:
ltcc.network@gmail.com

WEBSITE:
www.itcc-consortium.org
Institute for Pediatric Innovation’s Pediatric Hospital Consortium

The Consortium aims to create a network of collaborators to assist in translating innovations into commercially available solutions. It has previously launched initiatives to address unmet needs in nursing professional education, medical device development, and pediatric drug reformulation. IPI is working to administer a global design competition to develop a device for dispensing medicines that have been formulated using the company’s novel pediatric formulation technology.

MEMBERS:

Lucile Packard Children's Hospital Stanford
University Hospitals Rainbow Babies & Children's Hospital
Texas Children's Hospital
Shriners Hospitals for Children – Northern California

ASSOCIATE PARTNERS:

Children's Hospital of Orange County
Lehigh Valley Children's Hospital

CONTACT:

Stephen Evangelista, CEO of IPI
Tel. (617) 850-9060
E-Mail: communication@pediatricinnovation.org

Institute for Pediatric Innovation
10 Post Office Square
Suite 800, South
Boston, MA 02109

WEBSITE:

http://www.pediatricinnovation.org/consortium/
International Childhood Cancer Cohort Consortium at National Cancer Institute, Division of Cancer Epidemiology and Genetics (I4C)

The International Childhood Cancer Cohort Consortium is an alliance of large-scale prospective cohort studies of children to pool data and biospecimens from individual cohorts to study modifiable and genetic factors in relation to cancer risk. DCEG clinical studies do not evaluate treatment or other interventions, as in a clinical trial. I4C will initially concentrate on conducting studies of etiology of childhood leukemia.

CONTACT:

Martha S. Linet, M.D., M.P.H.
Senior Investigator
National Cancer Institute
Division of Cancer Epidemiology & Genetics,
Radiation Epidemiology Branch
9609 Medical Center Drive
Room 7E458
Phone: 240-276-7379
E-mail: linetm@mail.nih.gov

WEBSITE:


https://epi.grants.cancer.gov/Consortia/
Malignant Germ Cell International Consortium (MaGiC)

The Malignant Germ Cell International Consortium brings together international adult and pediatric oncologists, surgeons, pathologists, epidemiologists, biostatisticians, and basic scientists to advance the field of germ cell tumor research and develop more effective treatments. Its three main arms of research are: Clinical Trials Design & Development, Biologic Research, and Clinical Research. Currently it has 4 open clinical trials.

AFFILIATE ORGANIZATIONS:

- Children's Oncology Group
- NRG Oncology
- Cancer Research UK Clinical Trials Unit
- Children's Cancer and Leukemia Group
- Medical Research Council
- Brazilian Germ Cell tumor Committee
- SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent)

CONTACT:

MaGiC Headquarters
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
617-632-4808
magic@dfci.harvard.edu

WEBSITE:

https://www.magicconsortium.com

CHAIR:

Lindsay Frazier, MD
Associate Professor of Pediatrics
Harvard Medical School
Tel. 617-632-2273
E-mail: lindsay_frazier@dfci.harvard.edu
Medulloblastoma Advanced Genomics International Consortium (MAGIC)

An international consortium that performs genomic analyses of pediatric medulloblastoma samples, studying mRNA and miRNA expression profiles representing all four subgroups to identify novel subtypes within each subgroup, with and additional genomic DNA analysis of high-risk subgroup cases. The goal is to inform global childhood clinical trials consortia to initiate trials of therapy-sparing treatment of medulloblastoma.

MEMBERS:

Hospital for Sick Children
BC Cancer Agency - Michael Smith Genome Sciences Centre
McGill, University Health Centre
University of Calgary
University of Toronto
German Cancer Research Center
Harvard Medical School
University of British Columbia

CONTACT:

Dominik Stoll, Project Manager
Genome Sciences Centre, BC Cancer Agency
Email: dstoll@bcgsc.ca
Tel. 604-707-5900 x 675410

WEBSITE:

http://www.bcgsc.ca/project/magic
Mount Sinai Acute GVHD International Consortium (MAGIC)

Founded in 2014, MAGIC is a consortium of bone marrow transplantation (BMT) centers in the USA, Europe and Asia that conducts clinical trials to prevent and treat acute Graft Versus Host Disease (GVHD). The consortium has developed the “MAGIC Algorithm” to predict whether blood cancer patients who received a bone marrow transplant will develop GVHD. It also developed guidelines through international expert consensus opinion to standardize the diagnosis and clinical staging of GVHD for use in a large international GVHD research consortium.

MEMBERS:

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
BMT Program, University of Michigan
Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany
BMT Program, University of Regensburg, Germany
BMT Program, Ohio State University
BMT Program, Mayo Clinic
Pediatric BMT Program, Children's Hospital, University of Würzburg, Germany
Pediatric BMT Program, Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta
BMT Program, University of Pennsylvania
BMT Program, Chulalongkorn University, Bangkok, Thailand
Medical Department 1, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany
BMT Program, Massachusetts General Hospital
Hematology and Hematopoietic Cell Transplantation, City of Hope Medical Center
Department of Internal Medicine 5, Hematology/Oncology, University Hospital Erlangen-Nuremberg, Germany
Pediatric BMT Program, Vanderbilt University Medical Center
BMT Program, University of Utah

BMT Program, Columbia University
Biostatistics Shared Resource Facility, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Pediatric BMT Program, The Hospital for Sick Children, Toronto, Canada
Federal Center for Pediatric Hematology, Moscow, Russian Federation
Pediatric BMT Program, Ospedale Pediatrico Bambino Gesu, Rome, Italy
Department of Stem Cell Transplantation, University Medical Center, Hamburg-Eppendorf, Germany

DIRECTORS:

James L. M. Ferrara MD, DSc
Professor of Pediatrics
Director, Hematologic Malignancies
Translational Research Center
The Tisch Cancer Institute
james.ferrara@mssm.edu

John Levine, MD, MS
Professor of Pediatrics and Medicine, Hematology and Medical Oncology
The Tisch Cancer Institute
john.levine@mssm.edu

CONTACT:

Hess Center for Science and Medicine
470 Madison Avenue
6th Floor
New York, NY 10029

Tel: 212-824-9365
Fax: 646-537-9567

WEBSITE:

http://labs.icahn.mssm.edu/ferraralab/

http://www.bloodjournal.org/content/bloodjournal/131/25/2846.full.pdf?ss0-checked=true

National Experimental Therapeutics Consortium (NEXT)

The NEXT Consortium is a collaborative research model that seeks to expedite the most advanced treatments in the shortest time frame possible in pediatric oncology, hematology and bone marrow transplant. Currently NEXT is studying newly diagnosed medulloblastoma and CNS embryonal tumors in children. Its “Head Start 4” protocol is a tailored radiotherapy-avoiding approach to the treatment of newly diagnosed malignant central nervous system tumors of young children.

MEMBERS:

Children's of Alabama
Phoenix Children's Hospital
Children's Hospital Los Angeles
UCSF Oakland Benioff
Children's Hospital Orange County
Children's Hospital Colorado
Nemours Center for Cancer and Blood Disorders
Children's National Medical Center
Shands Children's Hospital/ University of FL
Nemours Center for Cancer and Blood Disorders
Miami Children's Hospital/Nicklaus
John's Hopkins All Children's Hospital
Children's Healthcare of Atlanta
Riley Children's Hospital/University of Indiana
University of Louisville School of Medicine
John's Hopkins University School of Medicine
University of Michigan
Helen DeVos
Masonic Children's Hospital/University of Minnesota
Joseph Sanzari Children's Hospital/
Hackensack University
Northwell Health
NYU Langone Medical Center
Columbus Presbyterian Children's Hospital
Memorial Sloan Kettering Cancer Center
SUNY
Carolina's HealthCare System/Levine Cancer Institute
Akron Children's Hospital
Cleveland Clinic

Nationwide Children's Hospital
Penn State Hershey Children's Hospital
Children's Hospital of Philadelphia
American Family Children's Hospital/University of Wisconsin
Medical College of Wisconsin
B.C. Children's Hospital (Canada)

PRINCIPAL INVESTIGATOR:

Jonathan Finlay, MD
Nationwide Children's Hospital

CONTACT:

Megan Jaeger, 614-722-3686
megan.jaeger@nationwidechildrens.org
Melinda Triplet, 614-722-6039
melinda.triplet@nationwidechildrens.org

WEBSITE:

NCI National Clinical Trials Network (NCTN) and NCI Community Oncology Research Program (NCORP)

The NCTN is a collection of organizations and clinicians that coordinates and supports cancer clinical trials at more than 3,000 sites across the United States and Canada. It includes four adult cooperative groups (SWOG, Alliance, NRG Oncology, ECOG-ACRIN) and the Children’s Oncology Group, which is focused solely on childhood cancers, and the Canadian Collaborating Clinical Trials Network.

Investigators at community hospitals, medical centers and from overseas can participate in NCTN trials by either receiving research reimbursement directly from one of the network groups with which they are affiliated or they receive awards from the NCI Community Oncology Research Program (NCORP). Thirty US academic institutions have been awarded a Lead Academic Participating Site (LAPS) grant, which is a source of funding created especially for the NCTN. The sites are academic research institutions with fellowship training programs.

NCORP is a national NCI-supported network that designs and conducts prevention, quality of life, cancer care delivery research (CCDR) studies and participates in NCTN treatment clinical trials. NCORP is comprised of 7 Research Bases and 46 Community Sites.

The Research Bases are hubs for the network that design and spearhead the conduct of multi-center clinical trials and CCDR, and provide overall administration, data management, and compliance. The NCORP Community Sites accrue patients. The Sites are consortia of researchers, public hospitals, physician practices, academic medical centers, and other groups. Each NCORP Site is affiliated with multiple community healthcare centers, hospitals, and practices, with over 900 community locations in the NCORP network. Several sites serve pediatric patients.

RESEARCH BASES:

Alliance NCORP Research Base
https://www.allianceforclinicaltrialsinoncology.org/
Children's Oncology Group (COG)
https://www.childrensoncologygroup.org/
ECOG-ACRIN
https://ecog-acrin.org/
NRG Oncology https://www.nrgoncology.org/
SWOG
https://www.swog.org/
University of Rochester
https://urcc-ccop.com/ccop/
Wake Forest
https://school.wakehealth.edu/Research/Institute/

LAPS ACADEMIC INSTITUTIONS:

Case Western Reserve University – Case Comprehensive Cancer Center
Dana Farber/Harvard Cancer Center
Duke Cancer Institute at Duke University Medical Center
Emory University – Winship Cancer Institute
Fred Hutchinson Cancer Research Center
Indiana University Cancer Center
Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center
Mayo Clinic Cancer Center
Memorial Sloan Kettering Cancer Center
Norris Cotton Cancer Center at Dartmouth
Hitchcock Medical Center
Ohio State University Comprehensive
Cancer Center
Roswell Park Cancer Institute
Stanford University – Stanford Cancer
Institute
University of Alabama at Birmingham
University of California Davis
Comprehensive Cancer Center
University of Chicago Comprehensive
Cancer Center
University of Colorado Cancer Center
University of Michigan Comprehensive
Cancer Center
University of North Carolina Lineberger
Comprehensive Cancer Center
University of Oklahoma – Stephenson
Cancer Center
University of Pittsburgh Cancer Institute
University of Southern California – Norris
Comprehensive Cancer Center
University of Texas MD Anderson Cancer
Center
University of Texas Southwestern Medical
Center – Harold C. Simmons Cancer
Center
University of Utah - Huntsman Cancer
Institute
University of Wisconsin Carbone Cancer
Center
Vanderbilt University Medical Center -
Vanderbilt Ingram Cancer Center
Washington University at St. Louis –
Siteman Cancer Center
Wayne State University Barbara Ann
Karamanos Cancer Institute
Yale University – Yale Cancer Center

NCORP COMMUNITY SITES:
https://ncorp.cancer.gov/findasite/

WEBSITE:
https://www.cancer.gov/research/areas/clinical-trials/nctn
New Approaches to Neuroblastoma Therapy (NANT)

Established in 2000, NANT is dedicated to developing novel treatments and biomarkers through early clinical trials (Phase I/II) for children whose disease has become resistant to front-line therapies. NANT brings together a multidisciplinary team of laboratory and clinical scientists from 14 pediatric hospitals and institutions in the U.S. and Canada. Currently NANT has 8 active trials.

MEMBERS:

Children's Healthcare of Atlanta (CHOA)
Children's Hospital Colorado
Children's Hospital Los Angeles
Cincinnati Children's Hospital Medical Center
Children's Hospital of Philadelphia
Cook Children's Health Care System
C.S. Mott Children's Hospital, University of Michigan
Children's Hospital Boston, Dana-Farber Cancer Institute
Lucile Packard Children's Hospital
Seattle Children's Hospital
Hospital for Sick Children
University of California, San Francisco
University of Chicago Comer Children's Hospital
University of North Carolina, Chapel Hill

SITE PRINCIPAL INVESTIGATORS:

http://www.nant.org/Patients_and_Families/institution.php

CONTACT:

NANT Operations Center
Children's Hospital Los Angeles
4650 Sunset Boulevard, MS #54
Los Angeles, CA 90027-6016
Phone: (323) 361-5687
Fax: (323) 361-1803
E-mail: nantops@chla.usc.edu

WEBSITE:

www.nant.org
North American Consortium for Histiocytosis (NACHO)

Formed in 2014, NACHO consists of 12 institutions dedicated to developing a research infrastructure to implement clinical and translational studies and conduct biological research of histiocytic diseases. Its aims to define the pathogenesis of histiocytic diseases and develop risk-stratification strategies with tissue samples from patients treated on NACHO trials. There are currently 3 active NACHO clinical studies.

MEMBERS:
Arkansas Children's Hospital  
The Children's Hospital of Philadelphia  
Children's National Medical Center  
Cincinnati Children's Hospital Medical Center  
Dana-Farber/Boston Children's Cancer and Blood Disorders Center  
Icahn School of Medicine at Mount Sinai  
Phoenix Children’s Hospital  
The Hospital for Sick Children (Canada)  
St. Jude Children’s Research Hospital  
Texas Children's Hospital/Baylor College of Medicine  
University of California San Francisco  
Children's Hospital Los Angeles  
Valley Children's Hospital  
Memorial Sloan Kettering Cancer Center  
Madigan Army Medical Center  
Columbia University/Herbert Irving Comprehensive Cancer Center  
Toledo Children's Hospital  
Sacred Heart Medical Center and Children’s Hospital

PRINCIPAL INVESTIGATORS:
Carlos Rodriguez-Galindo, MD  
Consortium Principal Investigator  
Director, NACHO Operations Center  
St. Jude Children’s Research Hospital

Carl Allen, MD, PhD  
Consortium Co-Principal Investigator  
Director, NACHO Biology Center  
Texas Children’s Cancer Center

ASSOCIATE MEMBERS:
Children's Healthcare of Atlanta  
Children's Hospitals and Clinics of Minnesota  
Connecticut Children's Medical Center  
Hackensack University Medical Center  
Ann & Robert H. Lurie Children's Hospital of Chicago  
SUNY Upstate Medical University  
American Family Children's Hospital  
Children's Mercy Hospital  
John's Hopkin's University  
Levine Children's Hospital  
Stanford University School of Medicine  
Staten Island University Hospital at Northwell Health  
Steven & Alexandra Cohen Children's Medical Center of New York  
The University of Texas Southwestern Medical Center

CONTACT:
Sara Clyburn, Consortium Project Coordinator, at NACHO@stjude.org.

WEBSITE:
https://www.nacho-consortium.org/
North American Pediatric Aplastic Anemia Consortium (NAPAAC)

NAPAAC is a collaborative research effort that seeks to develop better therapies for children with aplastic anemia by combining the expertise and resources of the leading pediatric hematologists in North America. Boston Children’s Hospital serves as the data coordinating center for the Consortium by providing infrastructure and technical support. Currently NAPAAC is conducting a pilot study (TransIT) to determine whether it is feasible to identify an unrelated bone marrow donor for newly diagnosed patients and to treat such patients with stem cell transplant (SCT) without initial immunsuppressive therapy (IST).

MEMBERS:

Boston Children's Hospital
Brown University / Hasbro Children's Hospital
Children's Hospital of Philadelphia
Hospital for Sick Children / University of Toronto
Johns Hopkins Medical Institute
Joseph M. Sanzari Children's Hospital / Hackensack University Medical Center
Northwell Health / Cohen Children's Medical Center
Yale University
Arkansas Children's Hospital
Duke University
Children's Hospital of Atlanta / Emory University
St. Jude Children's Research Hospital
University of Florida, Gainesville
Baylor College of Medicine / Texas Children's Hospital
Children's Hospital and Medical Center Omaha
Cleveland Clinic Children's
Lurie Children's Hospital- Northwestern Medical College of Wisconsin
Nationwide Children's Hospital / Ohio State University
Riley Children's Hospital / Indiana University
University of Michigan / CS Mott Children's Hospital
University of Texas Southwestern /

Children's Health Dallas
University of Wisconsin, Madison
Children's Hospital of Colorado
Children's Hospital of Los Angeles
Oregon Health and Science University
Phoenix Children's Hospital
Seattle Children's Hospital
Stanford University
UC San Francisco / Benioff Children's Hospital

CONTACT:

Tim Colby, NAPAAC Administrator
Phone: 617-919-6114
Email: Timothy.Colby@childrens.harvard.edu

Maggie Malsch, Project Manager
Phone: 617-355-4685
Email: Maggie.Malsch@childrens.harvard.edu

WEBSITE:

http://www.napaac.org/
Oncofertility Consortium

The Oncofertility Consortium is a national, interdisciplinary initiative designed to explore the reproductive future of cancer survivors. It addresses the complex health care and quality-of-life issues that concern young cancer patients whose fertility may be threatened by their disease or its treatment. The consortium provides information on how to establish a multidisicplinary oncofertility program, offers cryopreservation services and has created OC-Scientific Help Agreement for Research Endeavors program to help the scientific community carry out basic research. It currently has 105 participating hospitals or clinical centers in the U.S and over 100 outside the U.S.

DIRECTOR:
Teresa K. Woodruff, PhD  
Chief of the Division of Reproductive  
Science in Medicine, Feinberg  
School of Medicine  
Dean and Associate Provost for Graduate  
Education, Northwestern University  
E-mail: tkw@northwestern.edu

CONTACT:
Oncofertility Consortium  
303 E Superior Street, Suite 10-121  
Chicago, IL, 60611  
Tel. (312) 503-2504  
E-mail: oncofertility@northwestern.edu

WEBSITE:
http://oncofertility.northwestern.edu/
Pacific Pediatric Neuro-Oncology Consortium (PNOC)

PNOC is a network of 18 children’s hospitals that conduct clinical trials of new therapies for children with CNS malignancies. PNOC conducts early phase clinical trials to target specific pathways or molecularly characterized alterations with drugs or strategies specific to each patient. Currently it has 8 active trials at 18 participating sites.

MEMBERS:
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Children's Hospital Los Angeles
University of California, San Francisco
University of California, San Diego Rady Children's Hospital
University of Utah
Children's National Medical Center
Doernbecher Children's Hospital Oregon Health & Science University (OHSU)
Ann & Robert H. Lurie Children's Hospital of Chicago
Children's Hospital of Philadelphia
Nationwide Children's Hospital
St. Louis Children's Hospital
Seattle Children's Hospital
St. Jude Children's Research Hospital
Johns Hopkins Hospital
Children's Minnesota
Texas Children's Hospital
University of Minnesota/Masonic Cancer Center
University of Florida Shands Children's Hospital
Hospital for Sick Children

PROJECT LEADERS:
Sabine Mueller, MD, PhD
Assistant Professor of Neurology, Pediatrics and Neurological Surgery, UCSF
University of California, San Francisco
675 Nelson Lane Ring, Room 402
San Francisco, CA 94158
Email: sabine.mueller@ucsf.edu
Phone: (415) 476-3831

Michael Prados, MD
Professor and Charles B. Wilson Endowed Chair of Neurological Surgery, UCSF
University of California, San Francisco
1450 3rd St, Room HD 487 D
San Francisco, CA 94158-0520
Email: michael.prados@ucsf.edu
Phone: (415) 476-7217

WEBSITE:

www.pnoc.us
Pediatric Blood and Marrow Transplant Consortium (PBMTCP)

Founded in 1989, PBMTCP is a core member of the NIH-funded Blood and Marrow Transplant (BMT) Clinical Trials Network with a collaborative relationship with the Children's Oncology Group (COG). It is focused exclusively on blood and marrow transplants for children and adolescents. The consortium includes more than 100 pediatric BMT centers in the United States, Canada, New Zealand, Australia, Thailand and Czech Republic. Full Institutional Members are those that have FACT accreditation and are COG Transplant centers. Full members are the only members that are able to open clinical trials through the PBMTCP. Currently it participates in 5 active clinical trials.

**FULL MEMBERS:**

The Hospital for Sick Children
New York Medical College
University of Chicago
Nicklaus Children’s Hospital
Children's Hospital at Montefiore
Cleveland Clinic Children’s
Wayne State University
Washington University-St. Louis Children
UT Southwestern Medical Center at Dallas
University of Wisconsin Hospital and Clinics
University of Rochester Medical Center
University of Oklahoma Health Sciences Center
University of North Carolina, Chapel Hill
University of Nebraska Medical Center
University of Mississippi Medical Center
University of Minnesota Medical Center
University of Miami Miller School of Medicine - Sylvester Cancer Center
University of Iowa Children’s Hospital
University of Florida
University of Alabama at Birmingham
UCLA School of Medicine
UCLA David Geffen School of Medicine
The University of Arizona Medical Center
The Steven and Alexandra Cohen Children’s Hospital of New York
The Montreal Children's Hospital of the MUHC
The Children’s Hospital at Westmead
Texas Transplant Institute, Methodist Children's Hospital of South Texas
Sydney Children's Hospital
Starship Children's Hospital
Seattle Children
Saint Jude Children's Research Hospital
Royal Children's Hospital, Brisbane
Royal Children's Hospital
Roswell Park Cancer Institute
Riley Hospital for Children-Indiana University
Rainbow Babies and Children's Hospital
Rady Children's Hospital - San Diego
Princess Margaret Hospital for Children
Primary Children's Medical Center
Yale University
Phoenix Children's Hospital
Penn State Hershey Children's Hospital
Oregon Health and Science University-Doernbecher Children's Hospital
Nemours Children
Nationwide Children's Hospital
Midwest Children's Cancer Center
Medical University of South Carolina
MD Anderson Cancer Center
Mayo Clinic
Lucille Packard Children's Hospital Stanford University
Loma Linda University Medical Center
Kosair Children's Hospital
Johns Hopkins Hospital
Hospital Sainte-Justine
Helen Devos Children's Hospital
Hackensack University Medical Center
Floating Hospital for Children at Tufts Medical Center
Duke University Medical Center
Dana-Farber Cancer Institute
Cook Children's Medical Center
Columbia University Medical Center
City of Hope
Cincinnati Children's Hospital Medical Center
Children's of New Orleans/LSUMC
Children's National Medical Center
Children's Mercy Hospital
Children's Hospital of Philadelphia
Children's Hospital of Orange County
Children's Hospital of Los Angeles
Children's Hospital Colorado
Children's Hospital & Research Center at Oakland
Children's Healthcare of Atlanta
Carolinas Medical Center / Levine Children's Hospital
Cardinal Glennon Children's Medical Center-Saint Louis University
CancerCare Manitoba
C S Mott Children's Hospital
Mount Sinai
Vanderbilt University
British Columbia Children's Hospital
Baylor College of Medicine
Ann and Robert H. Lurie Children's Hospital of Chicago
All Children's Hospital
Alfred I. duPont Hospital for Children /
Nemours
Alberta Children's Hospital

CONTACT:
Laura Hancock
PBMTC Operations Center
Children's Hospital Los Angeles
4650 Sunset Blvd; Mail Stop #54
Los Angeles, CA 90027
Phone: (323) 361-4506
lahancock@pbmtc.org

WEBSITE:
http://www.pbmtc.org/
Pediatric Brain Tumor Consortium (PBTC)

Formed by the National Cancer Institute (NCI) in 1999 to improve the treatment of primary brain tumors in children, the Pediatric Brain Tumor Consortium is composed of 12 U.S. academic centers and children's hospitals with clinical expertise in pediatric brain tumors. It has completed 35 studies and has 8 active therapeutic studies.

MEMBERS:

- Children's Hospital Los Angeles
- Lucile Packard Children's Hospital Stanford
- Children's Hospital Colorado
- Children's National Medical Center
- Children's Healthcare of Atlanta
- Ann & Robert H. Lurie Children's Hospital of Chicago
- NIH-Pediatric Oncology Branch
- Memorial Sloan Kettering Cancer Center
- Cincinnati Children's Hospital Medical Center
- Children's Hospital of Pittsburgh
- St. Jude Children's Research Hospital
- Texas Children's Cancer Center

LEADERSHIP:

- Ira Dunkel, M.D., Chair
  Memorial Sloan Kettering Cancer Center
  Phone: (212) 639-2153
  Email: dunkeli@mskcc.org

- Jason Fangusaro, M.D., Vice-Chair
  Ann & Robert H. Lurie Children's Hospital of Chicago
  Phone: (312) 227-4846
  Email: jfangusaro@luriechildrens.org

WEBSITE:

www.pbtc.org
Pediatric Oncology Experimental Therapeutics Investigators’ Consortium (POETIC)

Founded in 2003, POETIC includes 10 academic centers in the U.S. and Canada which promote the early clinical development of therapies for the treatment of children, adolescents, and young adults with cancer and related disorders. The consortium has evolved from a clinical trials network to a research business enterprise. POETIC consists of two areas of programmatic focus arms: the POETIC Early Clinical Trials Program and the POETIC Translational Genomics Program. It currently has 4 ongoing trials, and has completed 13 trials.

MEMBERS:

Alberta Children's Hospital
Huntsman Cancer Institute
Memorial Sloan-Kettering Cancer Center
Arkansas Children's Hospital
Lucile Salter Packard Children's Hospital
Penn State Hershey Children's Hospital
University of Texas Health Science Center
Arnold Palmer Hospital for Children
MD Anderson Cancer Center
Phoenix Children's Hospital

DIRECTOR:

Dr. Tanya Trippett, Memorial Sloan Kettering Cancer Center (MSKCC)

CONTACT:

POETIC@poeticphase1.org
Tel. (877) 769-4828

The POETIC Data and Coordinating Center
C/O Memorial Sloan-Kettering Cancer Center
405 Lexington Avenue, Room 3-512
New York, NY 10174

WEBSITE:

www.poeticphase1.org
Pediatric Patient Reported Outcomes in Chronic Diseases Consortium (PEPR)

Funded by the National Institutes of Health and administered by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the PEPR Consortium is dedicated to the clinical evaluation of pediatric patient-reported outcomes among children with chronic diseases, including a study on adverse events of active treatment of cancer and a study on cancer survivorship. It captures experiences of children and their families using PROMIS measures. PEPR includes 6 performance sites and 82 collaborating sites.

MEMBERS:
The Children's Hospital of Philadelphia
Northwestern University
Medical College of Wisconsin
Duke University

CONTACT:
Children's Hospital of Philadelphia
Roberts Center for Pediatric Research
Center for Applied Clinical Research/PEDSnet
2716 South Street – 11th Floor
Philadelphia, PA 19146-2305

E-mail: PEPR@email.chop.edu

WEBSITE:
https://www.peprconsortium.org/
Pediatric Preclinical Testing Consortium (PPTC)

Funded by the National Cancer Institute, the PPTC consists of a Coordinating Center as well as five Research Programs that perform in vivo testing of pediatric anticancer drug candidates. The consortium develops preclinical testing data for pediatric drug candidates using genomically characterized childhood cancer xenograft lines and testing 6 to 10 new agents (or combinations of agents) annually.

MEMBERS:
Greehey Children's Cancer Research Institute
The Children's Hospital of Philadelphia
Children’s Cancer Hospital, MD Anderson Cancer Center
Children's Cancer Institute (Australia)
Ann & Robert H. Lurie Children's Hospital of Chicago

COORDINATING CENTER:
Research Triangle Institute (RTI) International

Greg Gatto, PhD
Principal Investigator

CONTACT:
The scientific direction of the PPTC is determined by its Steering Committee, which is composed of the PIs of the Research Programs and Coordinating Center and of the NCI Program Director (Dr. Malcolm Smith) and NCI Steering Committee Representative (Dr. Beverly Teicher).
E-mail: ncipptc@rti.org

WEBSITE:
http://www.ncipptc.org
Pediatric Proton Consortium Registry (PPCR)

Founded in 2012, PPCR is a multi-institutional radiation-based patient registry with 13 current participating sites and an additional 5 sites being on-boarded. Its goal is to expedite proton outcomes research to assure access to pediatric patients who can benefit the most from it. PPCR identifies patients for whom proton therapy offers a significant advantage over photon-based radiotherapy, and provides a platform for comparative research through Children’s Oncology Group (COG) and other consortia or databases. PPCR has accrued over 2,000 patients.

MEMBERS:
Massachusetts General Hospital
Northwestern Medicine Chicago Proton Center
University of Florida: Health Proton Therapy Institute
Washington University: S. Lee Kling Proton Therapy Center
MD Anderson Proton Therapy Center
University of Pennsylvania/ Perelman Center for Advanced Medicine
University of Washington/ Seattle Cancer Care Alliance
ProCure Proton Therapy Center- New Jersey
ProCure Proton Therapy Center- Oklahoma City
Mayo Clinic Rochester: Proton Beam Therapy Program
Texas Center for Proton Therapy
Maryland Proton Treatment Center
Cincinnati Children’s Hospital Proton Center

PRINCIPAL INVESTIGATOR:
Torunn I. Yock, MD, MCH
Massachusetts General Hospital
tyock@mgh.harvard.edu

CONTACT:
Sara Gallotto, Project Manager,
Massachusetts General Hospital
gallotto@mgh.harvard.edu
Tel: 617-643-9947

WEBSITE:
Sanford Children’s Genomic Medicine Consortium

Founded in 2018, the consortium consists of 7 children's hospitals committed to improving children's health by integrating genomic medicine into pediatric care. It works on improving diagnosis and treatment in a host of common and rare childhood diseases, and improving genetic and genomic discovery through access to a large, racially and ethnically diverse population. The consortium is currently funding a study evaluating the routine use of an extensive, pediatric-focused, next generation sequencing panel in the diagnosis of childhood cancers.

MEMBERS:
Banner Children's at Diamond Children's Medical Center
Children's Hospital Colorado
Children's Hospital Los Angeles
Children's Minnesota
Nicklaus Children's Hospital
Rady Children's
Sanford Children's

DIRECTOR:
Gene Hoyme, M.D
Clinical professor, Division of Genetics and Behavioral Pediatrics
University of Arizona Department of Pediatrics and Banner Children’s – Diamond Children’s Medical Center
Tel. (520) 626-5175
E-mail: genehoyme@email.arizona.edu

CONTACT:
Via online form:
https://sanfordhealth.formstack.com/forms/contact_form_childrens_consortium

WEBSITE:
https://www.sanfordhealth.org/initiatives/childrens-genomic-medicine
Sarcoma Alliance for Research through Collaboration (SARC)

A nonprofit consortium of sarcoma physicians founded in 2002, SARC includes researchers and investigators at sarcoma centers working together with pharmaceutical and biotech companies. SARC’s resources include access to the SARC Biospecimen Bank, SARC Clinical Data Repository, SARC Imaging Resources, and the sarcoma drug response portal. SARC has 6 active trials and 15 closed trials.

MEMBERS:

University of Alabama at Birmingham
Mayo Clinic / Arizona
Phoenix Children’s Hospital
University of Arizona Cancer Center
Arkansas Children’s Hospital
Cedars-Sinai Medical Center
Children’s Hospital and Research Center
Oakland
Children’s Hospital Los Angeles
City of Hope
Kaiser Permanente
Mattel Children’s Hospital UCLA
Sarcoma Oncology Research Center
Stanford Health Care
University of California / Los Angeles
University of California / San Francisco
University of Southern California / Norris Comprehensive Cancer Center
University of Colorado Denver – Ansultz Medical Campus
Yale Cancer Center / Smilow Cancer Hospital
Children’s National Medical Center
MedStar Washington Hospital Center
Mayo Clinic / Florida
Moffitt Cancer Center
Sylvester Comprehensive Cancer Center
University of Miami
University of Florida - College of Medicine
Emory University / Winship Cancer Institute
Northside Hospital Cancer Institute
Summit Cancer Centers
Ann & Robert H. Lurie Children’s Hospital of Chicago
Loyola University Medical Center
NorthShore University Health System
Oncology Specialists SC (OSSC)

Robert H. Lurie Comprehensive Cancer Center
Center of Northwestern University
Rush University Medical Center
Indiana University School of Medicine
University of Iowa Hospitals & Clinics – Holden Comprehensive Cancer Center
University of Kansas Cancer Center
Johns Hopkins University
LifeBridge Health Alvin & Lois Lapidus Cancer Institute, Sinai Hospital of Baltimore
National Cancer Institute
University of Maryland, Greenebaum Comprehensive Cancer Center
Dana Farber Cancer Institute
Massachusetts General Hospital
Helen DeVos Children’s Hospital
University of Michigan
Children’s Hospitals and Clinics Minnesota
Mayo Clinic / Rochester
University of Minnesota
Washington University in St. Louis
Nebraska Methodist Hospital
Dartmouth-Hitchcock Norris Cotton Cancer Center
MD Anderson Cancer Center / Cooper Health System
Columbia University Medical Center
Memorial Sloan-Kettering Cancer Center
Montefiore Medical Center
Mount Sinai Hospital (New York)
Northwell / Monzer Cancer Center
Roswell Park Cancer Institute
Carolinas Healthcare System / Levine Cancer Institute
Duke Cancer Institute
University of North Carolina at Chapel Hill
Cincinnati Children’s Hospital Medical Center
Center
Cleveland Clinic Foundation
Ohio State University Comprehensive Cancer Center
University Hospitals Case Medical Center
Children's Hospital at OU Medical Center
Oregon Health & Science University
Children's Hospital of Philadelphia
Fox Chase Cancer Center
University of Pennsylvania
UPMC Cancer Center (University of Pittsburgh)
Medical University of South Carolina – Hollings Cancer Center
St. Jude Children's Research Hospital
Vanderbilt University Medical Center / Vanderbilt-Ingram Cancer Center
West Cancer Center
Baylor University Medical Center
Texas Children's Hospital
University of Texas MD Anderson Cancer Center
UT Southwestern Medical Center
Huntsman Cancer Institute / University of Utah
University of Vermont Medical Center
Virginia Commonwealth University
Seattle Children's Hospital
University of Washington Cancer Center / Seattle Cancer Care Alliance
WVU Medicine Mary Babb Randolph Cancer Center
Aurora Health Care
Medical College of Wisconsin / Froedtert Hospital & Children's Hospital of Wisconsin

PRESIDENT AND CEO:
Denise Reinke, MS, NP, MBA

CONTACT:
Email: sarc@sarctrials.org
Phone: 734.930.7600
Fax: 734.930.7557

SARC
24 Frank Lloyd Wright Dr.
Lobby A, Suite 3100
Ann Arbor, MI 48105

WEBSITE:
https://sarctrials.org
South Plains Oncology Consortium (SPOC)

SPOC is a regional consortium located in Texas devoted to conducting early phase oncology trials and translational research. SPOC participates in the Texas Cancer Research Biobank at Baylor College of Medicine. SPOC investigators also established the Texas Cancer Cell Repository. It currently has 6 open clinical trials.

MEMBERS:

Children's Cancer Hospital, The University of Texas, MD Anderson Cancer Center
Children’s Hospital Los Angeles
Children's Hospital of Philadelphia
Cincinnati Children's Hospital Medical Center
Cook Children's Medical Center
Don and Sybil Harrington Cancer Center
Medical College of Wisconsin/Children's Hospital of Wisconsin
Stanford University
Texas Tech University Health Sciences Center/University Medical Center
The Joe Arrington Research and Treatment Center at Covenant Health System
University of Chicago
University of California, San Francisco
University of Oklahoma Health Sciences Center
University of Texas Health Sciences Center San Antonio
University of Texas Southwestern Medical Center
William Beaumont Army Medical Center

DIRECTORS:

C. Patrick Reynolds, MD, PhD
Email: patrick.reynolds@ttuhsc.edu

SPOC Director of Medical Oncology
Sanjay Awasthi, MD
Email: sanjay.awasthi@ttuhsc.edu

CONTACT:

Amanda Knight, RN, BSN, CCRP
Operations Center Manager
South Plains Oncology Consortium
Texas Tech University Health Science Center
3601 4th St, Mailstop 9440
Lubbock, TX 79430
Phone: (806) 743-2690

WEBSITE:

https://www.sponc.org/index.php
Southwest Oncology Group Cancer Research Network (SWOG)

SWOG is a global cancer research community that designs and conducts publicly funded clinical trials. The NCI is SWOG’s primary funder. SWOG includes over 1,000 institutions and has members in 47 states and six countries as part of the NCI’s National Clinical Trials Network. It runs trials in adults, some of which are open to children and adolescents. It currently has 71 open trials. SWOG is based at the Knight Cancer Institute at Oregon Health & Science University.

INSTITUTIONS:

https://www.swog.org/clinical-trials/institutions

PARTNERS:

Cold Spring Harbor Laboratory
The Jackson Laboratory
Cancer Research and Biostatistics
Nationwide Children’s Hospital
Knight Cancer Institute at OHSU
Fred Hutchinson Cancer Research Center

CONTACT:

SWOG Cancer Research Network
Group Chair’s Office
2611 SW 3rd Avenue MQ280
Portland, OR 97201
Phone: (503) 494-5586
Fax: (503) 346-8038

info@swog.org

WEBSITE:

https://www.swog.org

LEADERSHIP:

Charles D. Blanke, MD
Group Chair
Professor of Medicine
Knight Cancer Institute
Oregon Health & Science University
blankec@ohsu.edu

Anne F. Schott, MD
Deputy Chair and Vice Chair of National Clinical Trials Network Research
Professor of Internal Medicine
University of Michigan
St. Jude Children's Research Hospital

One of the largest pediatric cancer hospitals in the world, St. Jude treats about 8,500 patients each year. Its affiliate program is a network of pediatric hematology-oncology clinics, hospitals and universities. It offers hundreds of ongoing trials, with close to 200 active trials for oncology patients.

**Affiliate Clinics:**

- The St. Jude Baton Rouge Affiliate Clinic (Louisiana)
- The St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital (North Carolina)
- The St. Jude Affiliate Clinic at Huntsville Hospital for Women & Children (Alabama)
- The St. Jude Tri-Cities Affiliate Clinic (Tennessee)
- The Jim and Trudy Maloof St. Jude Midwest Affiliate Clinic (Illinois)
- Children's Hospital of LSU Health Sciences Center (Louisiana)
- The St. Jude Affiliate Clinic at Mercy Children's Hospital (Missouri)
- The St. Jude Affiliate Clinic at The Children's Hospital at Saint Francis (Oklahoma)

**Contact:**

St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105

Hospital Main Line: (866) 278-5833
Physician / Patient Referral Office:
(888) 226-4343
Email: referralinfo@stjude.org

**Website:**

[https://www.stjude.org](https://www.stjude.org)
Sunshine Project Consortium

The Sunshine Project Consortium consists of 12 institutions specializing in children’s oncologic care and conducting trials to find less toxic, more targeted therapies. The consortium develops phase I clinical trials for new drugs and new combinations of drugs for a variety of childhood cancers, with a strong focus on sarcomas. All Sunshine Project Trials are funded by the Pediatric Cancer Foundation. The Sunshine Project currently has 4 open clinical trials.

MEMBERS:
All Children’s Hospital Johns Hopkins Medicine
Children’s Hospital Los Angeles
Intermountain Primary Children’s Medical Center
Shands Children’s Hospital
Aldred I. duPont Hospital for Children /Nemours
Arnold Palmer Hospital for Children
The Children’s Hospital at Montefiore
Connecticut Children’s Medical Center
Holz Children’s Hospital /UM Jackson Memorial Health Center
Nemours Children’s Health System
Moffitt Cancer Center
MD Anderson Cancer Center

CHAIR:
Damon Reed, MD
Medical Director of the Sarcoma Program, Moffitt Cancer Center
Attending Physician, All Children’s Hospital
damonreed@moffitt.org
Tel. (813) 745-2297

CONTACT:
Kathleen Manning, MPH
Coordinator, Sunshine Project
kathleen.manning@moffitt.org
Tel. (813) 745-7412

WEBSITE:
https://www.sunshinetrials.org/ConsHome.asp
Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL)

Formed in 2005, TACL consortium is comprised of children's hospitals and universities that develop phase I/II clinical trials of new therapies and novel therapy combinations in recurrent childhood leukemia and lymphoma. It currently has 6 open clinical trials.

**MEMBERS:**

All Children's Hospital Johns Hopkins Medicine  
Associate Member: NCI, POB  
Associate Member: Sheba Medical Center  
BC Children's Hospital-Vancouver, Canada  
Children's Healthcare of Atlanta, Emory University  
Children's Hospital & Clinics of Minnesota  
Children's Hospital Colorado  
Children's Hospital Los Angeles  
Children's Hospital New York – Columbia Presbyterian  
Children's Hospital of Philadelphia  
Children's Hospital Orange County  
Children's National Medical Center  
Cincinnati Children's Hospital Medical Center  
Cook Children's Medical Center  
CS Mott Children's Hospital  
Dana Farber Cancer Institute and Children's Hospital  
Hospital for Sick Children  
Levine Children's Hospital at Carolinas Medical Center  
Lurie Children's Hospital of Chicago  
Medical College of Wisconsin  
Nationwide Children's Hospital  
Oregon Health & Science University  
Primary Children's Hospital  
Rainbow Babies & Children's Hospital  
Royal Children's Hospital, Australia  
Sainte Justine University Center, Canada  
Seattle Children's Hospital  
Sidney Kimmel Cancer Center at Johns Hopkins  
The Children's Hospital at Westmead, Australia  
UCSF School of Medicine  
University of Miami Cancer Center  
University of Texas Southwestern Medical Center

**CONTACT:**

TACL Operations Center  
Children's Hospital Los Angeles  
4650 Sunset Boulevard, MS # 54  
Los Angeles, CA 90027-6016

Ellynore Florendo  
Clinical Research Consortia Coordinator  
Phone: (323) 361-3022  
Fax: (877) 904-2166  
E-mail: eflorendo@chla.usc.edu

Lei-Lani Miller  
Clinical Research Consortia Coordinator  
Phone: (323) 361-5429  
Fax: (877) 904-2166  
E-mail: lmiller@chla.usc.edu

**WEBSITE:**

[www.tacli.us](http://www.tacli.us)
Treehouse Childhood Cancer Initiative

The Treehouse Childhood Cancer Initiative is the pediatric cancer research arm of the University of California Santa Cruz Genomics Institute. It was established to analyze genomic data of children with cancer in the context of large data sets of both pediatric and adult cancers. Treehouse promotes the sharing of pediatric cancer genomic data as well as translation of the findings from this analysis to the clinical setting. The goal of Treehouse is to increase the number of pediatric cancer patients that benefit from the genomic characterization of their tumor. Treehouse analyzed data from over 200 children to date and has an active study at Stanford University.

MEMBERS:
University of California Santa Cruz -- Genomics Institute
British Columbia Children’s Hospital
Children’s Hospital of Orange County
Stanford Medicine – Lucile Packard Children’s Hospital
University of California San Francisco

CONTACT:
University of California Santa Cruz
Sinsheimer Laboratories, Room 220
1156 High Street
Santa Cruz, CA
Tel. 831-459-2856

WEBSITE:
https://treehousegenomics.soe.ucsc.edu/

PRINCIPAL INVESTIGATORS:
David Haussler, PhD
Scientific Director, UC Santa Cruz Genomics Institute
Tel: (831) 459-2105
Haussler@ucsc.edu

Olena Morozova Vaske, PhD
Founder & Scientific Lead, Treehouse Childhood Cancer Initiative, UCSC
olena@ucsc.edu
University of California Cancer Consortium

Formed in 2017, UC Cancer Consortium unites 5 comprehensive cancer centers that treat all types of cancers in adults and children. The Consortium’s cancer centers are the nation’s top recipient of research grants from the National Institutes of Health (NIH) and of cancer research grants from the National Cancer Institute (NCI). It currently conducts 194 pediatric trials.

MEMBERS:

UC Davis Comprehensive Cancer Center
UC San Francisco Helen Diller Family Comprehensive Cancer Center
UCLA Jonsson Comprehensive Cancer Center
UC Irvine Chao Family Comprehensive Cancer Center
UC San Diego Moores Cancer Center

LEADERSHIP:

UCSF
Chair
Alan Ashworth, PhD, FRS
President, UCSF Cancer Center
alan.ashworth@ucsf.edu
Administrator: Kate Shumate, MPA, CCRP
kate.shumate@ucsf.edu

UC Davis
Director: Primo (Lucky) N. Lara, Jr., MD
pnlara@ucdavis.edu
Administrator: Gina Dayton
gmdayton@ucdavis.edu

UCLA
Director: Michael Teitell, MD, PhD
MTeitell@mednet.ucla.edu
Administrative contact:
NPresseau@mednet.ucla.edu

UC Irvine

Director: Richard Van Etten, MD, PhD
vanetten@uci.edu
Administrator: Amy Barach
abarach@uci.edu

UC San Diego

Director: Scott Lippman, MD
slippman@ucsd.edu
Administrator: Shreya Kanodia
skanodia@ucsd.edu

WEBSITE:

https://www.uccancer.org/